8-K: PMV Pharma's Rezatapopt Shows Strong Phase 2 Ovarian Cancer Data

PMV Pharmaceuticals announced promising interim Phase 2 data for its monotherapy rezatapopt in solid tumors with a TP53 Y220C mutation, planning an NDA submission for platinum-resistant/refractory ovarian cancer by Q1 2027.

Summary

• Interim data from the PYNNACLE Phase 2 trial for rezatapopt monotherapy in advanced solid tumors with a TP53 Y220C mutation.
• Overall response rate (ORR) of 33% (32/97 patients) across all cohorts, with a median duration of response (DoR) of 6.2 months.
• In the ovarian cancer cohort, ORR was 43% (19/44 patients), with a median DoR of 7.6 months.
• Confirmed responses observed in eight tumor types: ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.
• Rezatapopt demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events (TRAEs) being Grade 1-2.
• Low rate of drug discontinuations due to TRAEs (3.7%).
• FDA feedback received on initial New Drug Application (NDA) submission strategy for platinum-resistant/refractory ovarian cancer.
• The company plans to enroll an additional 20-25 platinum-resistant/refractory ovarian cancer patients by Q1 2026.
• NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
• Strong balance sheet with $148 million cash as of June 30, 2025, providing cash runway through Q1 2027.

Sentiment

Score: 8

Explanation: The interim Phase 2 data for rezatapopt shows strong efficacy and a favorable safety profile in a high unmet need area (platinum-resistant/refractory ovarian cancer). The clear regulatory path with FDA feedback and a solid cash runway through Q1 2027 are significant positives. While clinical trials always carry inherent risks, the data presented is highly encouraging and suggests a promising future for the drug and the company.

Positives

• Overall response rate (ORR) of 33% across all cohorts in heavily pre-treated patients.
• Higher ORR of 43% in the ovarian cancer cohort, indicating strong efficacy in a high unmet need area.
• Median duration of response (DoR) of 6.2 months overall and 7.6 months in ovarian cancer, suggesting durable responses.
• Favorable safety and tolerability profile with mostly Grade 1-2 treatment-related adverse events (TRAEs) and a low discontinuation rate of 3.7%.
• Administration with food improved gastrointestinal tolerability.
• On-target activity supported by significant decreases in ctDNA TP53 Y220C Variant Allele Frequency (VAF), with 91% experiencing a decrease and 32% achieving complete clearance.
• FDA feedback supports an initial NDA submission strategy for platinum-resistant/refractory ovarian cancer.
• Strong balance sheet with $148 million cash as of June 30, 2025, providing a cash runway through Q1 2027.
• Rezatapopt is a first-in-class, orally available small molecule targeting a previously undruggable mutation (p53 Y220C).

Risks

• Preclinical studies and clinical trials may not be successful.
• The U.S. Food and Drug Administration (FDA) may not agree with the interpretation of clinical trial data.
• The company may decide, or the FDA may require, to conduct additional clinical trials or to modify ongoing trials, leading to delays or increased costs.
• Delays may be experienced in the commencement, enrollment, completion, or analysis of clinical testing for product candidates.
• Product candidates may not receive regulatory approval or be successfully commercialized.
• Unexpected adverse side effects or inadequate therapeutic efficacy of product candidates could delay or prevent regulatory approval or commercialization.
• The company may not be able to obtain additional financing on acceptable terms or at all.
• Global pandemics, other public health emergencies, or geopolitical tensions or conflicts may disrupt business, clinical trials, manufacturing, and supply chain.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

PMV Pharma plans to complete enrollment for an additional 20-25 platinum-resistant/refractory ovarian cancer patients by the end of Q1 2026. The company aims to submit a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer by the end of Q1 2027, with a potential U.S. launch in 2027. They also foresee future opportunities to expand rezatapopt beyond ovarian cancer into other solid tumors like endometrial and breast cancer, and potentially in combination therapies or hematologic malignancies.

Management Comments

• "These Phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a first-in-class therapy, has the potential to harness the power of p53 to address cancers with high unmet need." Deepika Jalota, Pharm.D., Chief Development Officer.
• "Since PMV Pharma’s inception, leveraging more than four decades of research experience, we have pioneered the discovery and development of small molecule therapeutics that are designed to selectively address this historically undruggable target." Deepika Jalota, Pharm.D., Chief Development Officer.
• "Today, we are one step closer to realizing our vision of developing therapies that reactivate specific mutant p53 proteins to restore their wild-type function." Deepika Jalota, Pharm.D., Chief Development Officer.
• "Looking ahead, we expect to complete enrollment in the Phase 2 portion of the PYNNACLE study by the first quarter of 2026 and plan to submit an NDA to the FDA for rezatapopt in the first quarter of 2027." Deepika Jalota, Pharm.D., Chief Development Officer.

Industry Context

The ovarian cancer treatment landscape has evolved towards more molecularly focused therapies, yet a high unmet medical need persists, particularly in platinum-resistant/refractory ovarian cancer (PROC) where prognosis remains devastating with median overall survival often less than 12 months. Current treatments, primarily chemotherapy, offer limited efficacy and often involve inconvenient IV administration and significant adverse events. Rezatapopt, as a first-in-class, orally available, biomarker-directed therapy targeting the TP53 Y220C mutation, positions itself as a differentiated alternative to existing options like bevacizumab and mirvetuximab soravtansine (for FR-positive patients), which also have their own limitations and toxicities. The broad identifiability of the TP53 Y220C mutation via existing NGS panels supports its commercial viability in a market increasingly adopting precision oncology approaches.

Comparison to Industry Standards

• Rezatapopt's 43% ORR and 7.6 months median DoR in platinum-resistant/refractory ovarian cancer (PROC) compares favorably to current standard-of-care options. For instance, adding bevacizumab to chemotherapy in PROC (AURELIA Phase 3) showed an ORR of 27.3% and mPFS of 6.7 months.
• Mirvetuximab soravtansine, approved for FR-positive PROC, demonstrated an ORR of 42.3% and mDoR of 6.8 months in the MIRASOL Phase 3 trial. Rezatapopt's efficacy is comparable to or slightly better than mirvetuximab soravtansine, but targets a different biomarker (TP53 Y220C vs. FR-alpha).
• The oral administration of rezatapopt offers a convenience advantage over IV administered chemotherapies and ADCs, which is a significant patient preference factor.
• The safety profile of rezatapopt, with mostly Grade 1-2 TRAEs and low discontinuation rates, appears differentiated from the broader toxicities associated with chemotherapy and ADCs, which can include severe hematologic, gastrointestinal, and specific ADC-related toxicities like ocular events or pneumonitis.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, clear regulatory path, and potential for significant market opportunity, which could lead to increased share price and long-term value.
• Patients (with TP53 Y220C mutation): Highly positive impact as rezatapopt offers a novel, effective, and well-tolerated oral treatment option for a previously undruggable mutation, particularly in platinum-resistant/refractory ovarian cancer where unmet need is high.
• Healthcare Providers: Provides a new, targeted therapeutic option for a specific patient population, potentially improving treatment outcomes and quality of life for patients.
• Employees: Positive impact due to the company's progress in drug development and potential commercial success, ensuring job security and growth opportunities.

Next Steps

• Complete enrollment for an additional 20-25 platinum-resistant/refractory ovarian cancer patients by Q1 2026.
• Conduct primary analysis of ovarian cohort data.
• Submit New Drug Application (NDA) to the FDA for platinum-resistant/refractory ovarian cancer by Q1 2027.
• Potential U.S. launch in 2027.
• Continue generating monotherapy data in Phase 2 PYNNACLE for other tumor types (endometrial, breast).
• Explore future opportunities for combination therapies and hematologic malignancies.

Key Dates

Recommendation

The interim Phase 2 data for rezatapopt demonstrates compelling efficacy (43% ORR in PROC, 33% overall) and a favorable safety profile in a heavily pre-treated patient population with a high unmet medical need. The drug targets a specific, previously undruggable mutation (TP53 Y220C) and has received positive FDA feedback for its NDA submission strategy, indicating a clear and accelerated path to market for platinum-resistant/refractory ovarian cancer by Q1 2027. The company's strong cash position ($148M through Q1 2027) provides financial stability for upcoming milestones. Given the significant market potential, the first-in-class nature of the therapy, and the strong clinical results, the stock presents a strong buying opportunity for investors seeking exposure to precision oncology with a de-risked asset.

Keywords

Rezatapopt, PMV Pharmaceuticals, PYNNACLE, Phase 2, Ovarian Cancer, TP53 Y220C, Solid Tumors, Oncology, Precision Medicine, FDA, NDA, Clinical Trial, Biotechnology, Cancer Treatment, Drug Development